How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,635 results for

Squamous Cell Carcinoma of the Skin

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

13861. Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer

Cardiovascular: No history of New York Heart Association class II-IV heart disease Pulmonary: No significant pulmonary disease requiring pulse steroid therapy within the past 3 months Other: No other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix No other serious concurrent medical illness that would preclude study participation No active infection Not pregnant or nursing Negative pregnancy test Fertile patients must use (...) Oncology Group: stage IV renal cell cancer recurrent renal cell cancer Additional relevant MeSH terms: Layout table for MeSH terms Kidney Neoplasms Carcinoma, Renal Cell Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Neoplasms Kidney Diseases Urologic Diseases Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Atrasentan Antineoplastic Agents Endothelin A Receptor Antagonists Endothelin Receptor Antagonists Molecular Mechanisms of Pharmacological Action

2002 Clinical Trials

13862. S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer

abnormalities due to cancer No prior severe hypersensitivity reaction to docetaxel or other drugs formulated with Polysorbate 80 No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other adequately treated stage I or II cancer currently in complete remission No known sensitivity to E. coli-derived proteins Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR (...) 6, 2013 Last Verified: May 2013 Keywords provided by Southwest Oncology Group: stage IV breast cancer recurrent breast cancer Additional relevant MeSH terms: Layout table for MeSH terms Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Docetaxel Trastuzumab Vinorelbine Lenograstim Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Immunological Adjuvants, Immunologic

2002 Clinical Trials

13863. Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver

infarction within six (6) months prior to this trial will be excluded. Patients with an indwelling cardiac pacemaker, cerebral aneurysm clips, or any other indwelling device or appliance that could be adversely affected by the use of the external magnet Patients at the time of study entry with a second invasive cancer other than basal cell and squamous cell carcinoma of the skin, or carcinoma in situ of the cervix Patients with documented evidence of hemachromatosis or hemosiderosis Patients with CT (...) by Site Breast Diseases Skin Diseases Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Intestinal Neoplasms Digestive System Diseases Gastrointestinal Diseases

2002 Clinical Trials

13864. S0029 Docetaxel in Treating Older Women With Metastatic Breast Cancer

metastases are present) Renal: Creatinine no greater than ULN Other: Not pregnant or nursing Fertile patients must use effective contraception HIV negative No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy for breast cancer Chemotherapy: Prior adjuvant or neoadjuvant (...) ) Information provided by (Responsible Party): Southwest Oncology Group Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating older women who have metastatic breast cancer. Condition or disease Intervention/treatment Phase Breast Cancer Drug: docetaxel Phase 2 Detailed Description: OBJECTIVES: Determine

2001 Clinical Trials

13865. Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx

No pre-existing uncontrolled cardiac disease No signs of cardiac failure No rhythm disturbances requiring medication Other: No sensory neuropathy grade 2 or greater unless due to cranial nerve No uncontrolled infections No sensitivity to aminothiol compounds No other malignancy within the past 5 years except adequately controlled carcinoma in situ of the cervix or basal cell or squamous cell skin cancer No psychological, familial, sociological, or geographical condition that would preclude study (...) -energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. Giving chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy and radiation therapy. PURPOSE: Randomized phase II trial to compare the effectiveness of paclitaxel and carboplatin followed by cisplatin plus radiation therapy with or without amifostine in treating patients who have locally advanced cancer of the nasopharynx. Condition or disease

2001 Clinical Trials

13866. Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix

substances to them. Condition or disease Intervention/treatment Phase Cervical Squamous Cell Carcinoma Recurrent Cervical Cancer Biological: bevacizumab Other: laboratory biomarker analysis Phase 2 Detailed Description: OBJECTIVES: I. Determine the cytostatic antitumor activity of bevacizumab, in terms of 6-month progression-free survival (PFS), in patients with persistent or recurrent squamous cell carcinoma of the cervix. II. Determine the nature and degree of toxicity of this drug in these patients (...) : Histologically confirmed persistent or recurrent squamous cell carcinoma (SCC) of the cervix Patients must have received at least 1, but no more than 2, prior cytotoxic chemotherapy regimens for advanced, metastatic, or recurrent SCC of the cervix Chemotherapy administered as a radio-sensitizer does not count as 1 regimen Documented disease progression At least 1 unidimensionally measurable lesion* At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan No tumor involving major blood

2001 Clinical Trials

13867. Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

mL/min Cardiovascular: No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other: No other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix No other uncontrolled concurrent illness No ongoing or active infection No psychiatric illness or social situation that would preclude study compliance No prior allergic reactions attributed to compounds of similar chemical or biologic (...) ) Information provided by (Responsible Party): National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: Phase II trial to study the effectiveness of gefitinib in treating patients who have recurrent and/or metastatic head and neck cancer. Biological therapies such as gefitinib may interfere with the growth of tumor cells by blocking an enzyme necessary for cell growth. Condition or disease Intervention/treatment Phase Head and Neck Cancer Drug: gefitinib Phase 2 Detailed

2001 Clinical Trials

13868. Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver

infarction within the past 6 months No evidence of congestive heart failure No severe peripheral vascular disease that would preclude catheterization Other: No severe allergy or intolerance to contrast media, narcotics, sedatives, or atropine No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix Not pregnant or nursing Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy (...) colon cancer recurrent rectal cancer adenocarcinoma of the colon adenocarcinoma of the rectum liver metastases Additional relevant MeSH terms: Layout table for MeSH terms Colorectal Neoplasms Adenocarcinoma Neoplasm Metastasis Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic

2001 Clinical Trials

13869. Surgery Versus Internal Radiation in Treating Patients With Stage II Prostate Cancer

the past 5 years except effectively treated basal cell or squamous cell skin cancer or other malignancy at low risk for recurrence No other condition that would preclude study PRIOR CONCURRENT THERAPY: Endocrine therapy: See Disease Characteristics At least 90 days since prior NHT Duration of therapy no greater than 120 days No concurrent NHT Radiotherapy: No prior radiotherapy to pelvis Surgery: No prior surgery for prostate cancer or benign disease, including: Transurethral resection of the prostate (...) Physician Data Query ) First Posted: January 27, 2003 Last Update Posted: July 6, 2016 Last Verified: July 2016 Keywords provided by Alliance for Clinical Trials in Oncology: adenocarcinoma of the prostate stage IIB prostate cancer stage IIA prostate cancer Additional relevant MeSH terms: Layout table for MeSH terms Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Genital Diseases, Male Prostatic Diseases

2001 Clinical Trials

13870. Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer

(GI) ulcer, GI bleeding, or inflammatory bowel disease No other prior malignancy within the past 5 years except cutaneous basal cell skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy: No recent prior celecoxib or other cyclo-oxygenase-2 inhibitor Chemotherapy: No prior systemic chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to pelvis except transvaginal radiotherapy to control bleeding Surgery: No prior surgery for cervical cancer except biopsy Other (...) : Other Study ID Numbers: RTOG-C-0128 CDR0000068849 First Posted: January 27, 2003 Last Update Posted: November 19, 2013 Last Verified: November 2013 Keywords provided by Radiation Therapy Oncology Group: stage III cervical cancer stage IB cervical cancer stage IIB cervical cancer stage IIA cervical cancer stage IVA cervical cancer cervical squamous cell carcinoma cervical adenocarcinoma cervical adenosquamous cell carcinoma Additional relevant MeSH terms: Layout table for MeSH terms Uterine Cervical

2001 Clinical Trials

13871. S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer

cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission No contraindication to receiving sargramostim (GM-CSF) or KLH-based vaccine products No autoimmune disease HIV negative Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics At least 1 month since prior cytotoxic chemotherapy (...) cancer stage III gastric cancer stage IV gastric cancer recurrent gastric cancer adenocarcinoma of the prostate stage II ovarian epithelial cancer stage III ovarian epithelial cancer stage IV ovarian epithelial cancer recurrent adult brain tumor stage IV prostate cancer recurrent prostate cancer adult anaplastic astrocytoma Additional relevant MeSH terms: Layout table for MeSH terms Prostatic Neoplasms Ovarian Neoplasms Carcinoma, Ovarian Epithelial Stomach Neoplasms Brain Neoplasms Genital Neoplasms

2001 Clinical Trials

13872. Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer

, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically confirmed invasive bladder cancer (T2-4a, N0, M0) Adenocarcinoma Transitional cell carcinoma Squamous cell carcinoma Localized muscle invasion by surgery or imaging PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-2 Life expectancy: Not specified Hematopoietic: WBC greater than 4,000/mm^3 Platelet count greater than 100,000/mm^3 Hepatic: Bilirubin less than (...) 1.5 times upper limit of normal (ULN) ALT or AST less than 1.5 times ULN Renal: Glomerular filtration rate greater than 25 mL/min Other: Not pregnant Negative pregnancy test Fertile patients must use effective contraception No inflammatory bowel disease No other prior malignancy within the past 2 years except adequately treated basal cell skin cancer or carcinoma in situ of the cervix No other prior malignancy or uncontrolled systemic disease that would preclude study participation PRIOR

2001 Clinical Trials

13873. Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer

treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix No other acute or chronic medical or psychiatric condition or laboratory abnormality that would preclude study participation No prior trastuzumab (Herceptin) No other concurrent immunologic therapy See Disease Characteristics Recovered from prior cytotoxic chemotherapy No prior cumulative dose of doxorubicin more than 360 mg/m^2 No concurrent chemotherapy At least 2 weeks since prior hormonal therapy No concurrent (...) with the growth of tumor cells and may enhance the effects of trastuzumab. Combining trastuzumab with gefitinib may be an effective treatment for metastatic breast cancers with high amounts of HER2 Condition or disease Intervention/treatment Phase Male Breast Cancer Recurrent Breast Cancer Stage IV Breast Cancer Biological: trastuzumab Drug: gefitinib Other: laboratory biomarker analysis Phase 2 Detailed Description: PRIMARY OBJECTIVES: I. Determine the response rate, duration of response, and time

2001 Clinical Trials

13874. Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer

of myocardial infarction No history of stroke No uncontrolled high blood pressure Other No uncontrolled metabolic or endocrine disease No malabsorption syndrome No known hypersensitivity to exemestane or its excipients No other malignancy within the past 5 years except curatively treated squamous cell or basal cell skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy No prior immunotherapy No concurrent immunotherapy Chemotherapy No prior chemotherapy No concurrent (...) ( NCIC Clinical Trials Group ): breast cancer Additional relevant MeSH terms: Layout table for MeSH terms Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Exemestane Antineoplastic Agents Aromatase Inhibitors Steroid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Estrogen Antagonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs

2003 Clinical Trials

13875. Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer

Verified: September 2012 Keywords provided by European Organisation for Research and Treatment of Cancer - EORTC: penile squamous cell carcinoma stage III penile cancer stage IV penile cancer Additional relevant MeSH terms: Layout table for MeSH terms Penile Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Genital Diseases, Male Penile Diseases Cisplatin Irinotecan Antineoplastic Agents Topoisomerase I Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular (...) Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically confirmed penile squamous cell carcinoma Locally advanced or metastatic disease T3, N1-2 OR T4, N3, M1 Measurable disease outside of any previously irradiated field No clinical signs of brain metastases PATIENT CHARACTERISTICS: Age 75 and under Performance status WHO 0-2 Life expectancy Not specified Hematopoietic Absolute neutrophil count at least 2,000/mm^3 Platelet count at least 100,000/mm^3 Hepatic Bilirubin no greater than 1.5 times

2003 Clinical Trials

13876. Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer

No known allergy to other platinum compounds No other malignancy within the past 5 years except basal cell or squamous cell skin cancer, carcinoma in situ, or tumors associated with less than 10% probability of death within 5 years of diagnosis No preexisting neuropathy ≥ grade 2 No symptomatic pulmonary fibrosis or interstitial pneumonitis No uncontrolled bacterial or viral infection HIV negative No fungal infection PRIOR CONCURRENT THERAPY: Biologic therapy No colony-stimulating factors within 24 (...) of the colon adenocarcinoma of the rectum Additional relevant MeSH terms: Layout table for MeSH terms Colorectal Neoplasms Adenocarcinoma Neoplasm Metastasis Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplastic Processes Pathologic Processes Calcium Oxaliplatin

2003 Clinical Trials

13877. Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia

cancer* Patients with curatively treated stage I or II squamous cell carcinoma of the head and neck (limited to oral cavity, pharynx, or larynx)* NOTE: *At least 12 months post-curative therapy Histologic confirmation of mild to severe bronchial dysplasia on bronchoscopic biopsy required Moderate or severe atypia on sputum cytology required before bronchoscopy (not required for patients with prior lung or head and neck cancer) No evidence of malignancy by chest x-ray PATIENT CHARACTERISTICS: Age 18 (...) , or a mixed drink per day on a regular basis) No other medical condition that would preclude safety during study participation No other active or invasive malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix No hypersensitivity to study drug or any of its inactive ingredients PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy Not specified Endocrine therapy More than 3 months since prior corticosteroids* No concurrent corticosteroids

2003 Clinical Trials

13878. T900607 in Treating Patients With Unresectable Liver Cancer

anticoagulants) Renal Creatinine no greater than 2 times ULN Cardiovascular LVEF at least 50% No New York Heart Association class III or IV cardiac disease No acute anginal symptoms Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 3 months after study No severe concurrent disease, infection, or co-morbidity that would preclude study entry No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin (...) by: National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of T900607 in treating patients who have unresectable liver cancer. Condition or disease Intervention/treatment Phase Liver Cancer Drug: T900607 Phase 2 Detailed Description: OBJECTIVES: Determine the complete and partial response rates of patients

2003 Clinical Trials

13879. T900607 in Treating Patients With Gastroesophageal Junction Cancer

the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix No severe infection No other concurrent severe medical condition or comorbidity that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy More than 7 days since prior growth factors or blood transfusions No concurrent therapeutic biological response modifier therapy No concurrent immunotherapy Chemotherapy See Disease Characteristics No other concurrent (...) ) Information provided by: National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of T900607 in treating patients who have gastroesophageal junction cancer. Condition or disease Intervention/treatment Phase Gastric Cancer Drug: T900607 Phase 2 Detailed Description: OBJECTIVES: Determine the response rate

2003 Clinical Trials

13880. Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix

carcinoma cervical squamous cell carcinoma stage IB cervical cancer Additional relevant MeSH terms: Layout table for MeSH terms Uterine Cervical Neoplasms Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Neoplasms Uterine Cervical Diseases Uterine Diseases Genital Diseases, Female (...) about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: Female Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically confirmed stage IB2 invasive carcinoma of the uterine cervix of one of the following types: Squamous cell carcinoma Adenocarcinoma Adenosquamous

2003 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>